Microsatellite-Stable Colorectal Cancer

COM701, a novel first-in-class immune checkpoint inhibitor, demonstrated antitumor activity alone and in combination with nivolumab among patients with advanced solid tumors, according to results of a phase 1 study presented at the virtual American Association for Cancer Research Annual Meeting.